AcelRx downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded AcelRx to Neutral citing an uncertain regulatory outlook for Zalviso after the company received a Complete Response Letter from the FDA. Piper lowered its price target for shares to $8 from $14.
AcelRx names Howard Rosen as interim CEO AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.